Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Assets AverageDebt RatioDebt to EquityEnterprise ValueEquity AverageEquity RatioInterest Coverage RatioInvested CapitalReturn on AssetsReturn on Capital EmployedReturn on EquityTimes Interest Earned

Candel Therapeutics (CADL) Equity Average (2020 - 2025)

Candel Therapeutics' Equity Average history spans 4 years, with the latest figure at $17.9 million for Q4 2023.

  • On a quarterly basis, Equity Average fell 64.18% to $17.9 million in Q4 2023 year-over-year; TTM through Dec 2023 was $17.9 million, a 64.18% decrease, with the full-year FY2023 number at $30.2 million, down 45.95% from a year prior.
  • Equity Average hit $17.9 million in Q4 2023 for Candel Therapeutics, down from $26.9 million in the prior quarter.
  • Over the last five years, Equity Average for CADL hit a ceiling of $63.9 million in Q1 2022 and a floor of -$35.3 million in Q2 2021.
  • Historically, Equity Average has averaged $24.0 million across 4 years, with a median of $31.1 million in 2023.
  • Biggest five-year swings in Equity Average: soared 466.32% in 2022 and later tumbled 64.18% in 2023.
  • Tracing CADL's Equity Average over 4 years: stood at -$19.2 million in 2020, then skyrocketed by 431.24% to $63.6 million in 2021, then fell by 21.46% to $49.9 million in 2022, then tumbled by 64.18% to $17.9 million in 2023.
  • Business Quant data shows Equity Average for CADL at $17.9 million in Q4 2023, $26.9 million in Q3 2023, and $35.2 million in Q2 2023.